Clinical Trial Detail

NCT ID NCT04471428
Title Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy (CONTACT-01)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Hoffmann-La Roche
Indications

lung non-small cell carcinoma

Therapies

Docetaxel

Atezolizumab + Cabozantinib

Age Groups: senior adult

Additional content available in CKB BOOST